D Orazio & Associates Inc. raised its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 0.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,816 shares of the biopharmaceutical company’s stock after buying an additional 1 shares during the period. D Orazio & Associates Inc.’s holdings in Gilead Sciences were worth $130,000 as of its most recent SEC filing.
A number of other large investors have also made changes to their positions in the company. Penserra Capital Management LLC boosted its stake in Gilead Sciences by 148.3% in the third quarter. Penserra Capital Management LLC now owns 1,296 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 774 shares during the last quarter. Gemmer Asset Management LLC boosted its stake in Gilead Sciences by 15.5% in the third quarter. Gemmer Asset Management LLC now owns 1,301 shares of the biopharmaceutical company’s stock worth $103,000 after buying an additional 175 shares during the last quarter. Lombard Odier Transatlantic Limited Partnership boosted its stake in Gilead Sciences by 55.6% in the third quarter. Lombard Odier Transatlantic Limited Partnership now owns 1,400 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 500 shares during the last quarter. Cable Hill Partners LLC boosted its stake in Gilead Sciences by 19.1% in the third quarter. Cable Hill Partners LLC now owns 1,639 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 263 shares during the last quarter. Finally, First Bank & Trust purchased a new stake in Gilead Sciences during the fourth quarter worth approximately $140,000. Institutional investors and hedge funds own 74.19% of the company’s stock.
Gilead Sciences, Inc. (NASDAQ:GILD) traded down 0.910% during midday trading on Friday, hitting $65.895. 4,349,301 shares of the stock traded hands. The stock has a 50-day moving average of $67.70 and a 200 day moving average of $71.79. The firm has a market cap of $86.13 billion, a PE ratio of 6.629 and a beta of 1.11. Gilead Sciences, Inc. has a 52-week low of $65.38 and a 52-week high of $103.10.
Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Tuesday, February 7th. The biopharmaceutical company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.61 by $0.09. Gilead Sciences had a return on equity of 92.36% and a net margin of 44.43%. The business earned $7.30 billion during the quarter, compared to the consensus estimate of $7.16 billion. During the same quarter in the previous year, the company posted $3.32 EPS. The business’s revenue was down 13.9% on a year-over-year basis. Equities analysts forecast that Gilead Sciences, Inc. will post $8.25 EPS for the current year.
The company also recently announced a quarterly dividend, which was paid on Thursday, March 30th. Investors of record on Thursday, March 16th were paid a $0.52 dividend. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.47. The ex-dividend date of this dividend was Tuesday, March 14th. This represents a $2.08 annualized dividend and a yield of 3.13%. Gilead Sciences’s payout ratio is presently 18.91%.
ILLEGAL ACTIVITY NOTICE: This report was first posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this report on another publication, it was stolen and reposted in violation of U.S. & international copyright laws. The correct version of this report can be read at https://www.chaffeybreeze.com/2017/04/21/gilead-sciences-inc-gild-stake-increased-by-d-orazio-associates-inc-updated.html.
A number of equities research analysts have recently commented on GILD shares. William Blair reiterated an “outperform” rating on shares of Gilead Sciences in a report on Saturday, January 28th. Cowen and Company set a $100.00 price objective on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Wednesday, January 18th. Zacks Investment Research downgraded shares of Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Monday, February 13th. Jefferies Group LLC restated a “buy” rating and set a $82.00 price objective on shares of Gilead Sciences in a research report on Thursday, April 6th. Finally, Goldman Sachs Group Inc restated a “hold” rating and set a $81.00 price objective on shares of Gilead Sciences in a research report on Friday, January 13th. Eleven analysts have rated the stock with a hold rating, fifteen have issued a buy rating and two have assigned a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $83.86.
In related news, EVP Gregg H. Alton sold 5,000 shares of the business’s stock in a transaction dated Thursday, March 30th. The shares were sold at an average price of $67.48, for a total value of $337,400.00. Following the completion of the transaction, the executive vice president now owns 117,988 shares of the company’s stock, valued at approximately $7,961,830.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Monday, April 3rd. The shares were sold at an average price of $67.18, for a total transaction of $4,926,510.94. Following the completion of the transaction, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $214,973,917.42. The disclosure for this sale can be found here. Insiders own 1.40% of the company’s stock.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.
Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.